Oral semaglutide: dosage in special situations
Xing D, Yoo C, Gonzalez D, Jenkins V, Nottingham K, Dickerson B et al (2021) Dose-response of Paraxanthine on cognitive function: a double blind, placebo controlled, crossover trial
The drug is being developed by Eli Lilly and Company and is currently progressing through Phase 3 clinical trials, which are required to demonstrate safety and efficacy in larger, more diverse populations over longer timeframes before a regulatory submission can be made
The added glucagon receptor activation may enhance fat oxidation and increase energy expenditure beyond what dual agonists achieve
Metabolic Improvements Beyond Weight Loss Weight loss gets the attention, but retatrutide also improved multiple metabolic markers
Its sold under a few different brand names including Ozempic, Wegovy (specifically approved for weight loss), and Rybelsus (an oral formulation of semaglutide)